Patents by Inventor Etienne Thoreau

Etienne Thoreau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors
    Patent number: 11731973
    Abstract: The invention relates to novel mTOR inhibitor compounds having the formula (I) or a pharmaceutically acceptable salt thereof, compositions comprising the mTOR inhibitor compounds, methods for producing the same, and the use thereof.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: August 22, 2023
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Laurence Clary, Jean-François Fournier, Gilles Ouvry, Yushma Bhurruth-Alcor, Etienne Thoreau, Loïc Tomas
  • NOVEL JAK INHIBITOR COMPOUNDS, METHODS FOR SYNTHESIZING SAME AND USE THEREOF
    Publication number: 20230212188
    Abstract: Novel compounds having formula (I) and methods of using these compounds to treat diseases, conditions, and disorders are described.
    Type: Application
    Filed: March 13, 2023
    Publication date: July 6, 2023
    Inventors: Gilles OUVRY, Branislav MUSICKI, Craig HARRIS, Etienne Thoreau
  • MTOR inhibitor compounds
    Patent number: 11518767
    Abstract: The invention relates to novel mTOR inhibitor compounds having the general formula (I), to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: December 6, 2022
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Laurence Clary, Jean-François Fournier, Gilles Ouvry, Yushma Bhurruth-Alcor, Etienne Thoreau, Loïc Tomas
  • NOVEL MTOR INHIBITOR COMPOUNDS
    Publication number: 20200317679
    Abstract: The invention relates to novel mTOR inhibitor compounds. The invention is characterized in that the mTOR inhibitor compounds have general formula (I). The invention also relates to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Laurence CLARY, Jean-François FOURNIER, Gilles OUVRY, Yushma BHURRUTH-ALCOR, Etienne THOREAU, Loïc TOMAS
  • MTOR INHIBITOR COMPOUNDS
    Publication number: 20200317683
    Abstract: The invention relates to novel mTOR inhibitor compounds. The invention is characterized in that the mTOR inhibitor compounds have general formula (I). The invention also relates to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Laurence CLARY, Jean-François FOURNIER, Gilles OUVRY, Yushma BHURRUTH-ALCOR, Etienne THOREAU, Loïc TOMAS
  • Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T))
    Patent number: 10752617
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: August 25, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Gilles Ouvry, Etienne Thoreau, Claire Bouix-Peter
  • Benzimidazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T))
    Patent number: 10618890
    Abstract: Benzimidazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 14, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Gilles Ouvry, Etienne Thoreau, Claire Bouix-Peter
  • Tetrahydroquinoline sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (t))
    Patent number: 10550110
    Abstract: Tetrahydroquinoline sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma (ROR?t) are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 4, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Claire Bouix-Peter, Gilles Ouvry, Etienne Thoreau
  • Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR?(T))
    Patent number: 10457637
    Abstract: Benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonist of retinoid-related orphan receptor gamma (ROR?t) are described. A pharmaceutical composition including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-medicated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 29, 2019
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Claire Bouix-Peter, Gilles Ouvry, Etienne Thoreau
  • INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20190202819
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 4, 2019
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav MUSICKI, Gilles OUVRY, Etienne THOREAU, Claire BOUIX-PETER
  • Heterocyclic compounds and use thereof in medicine and in cosmetics
    Patent number: 10246422
    Abstract: The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: April 2, 2019
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Francois Fournier, Laurence Clary, Etienne Thoreau
  • Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR ? (T))
    Patent number: 10246440
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 2, 2019
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Gilles Ouvry, Etienne Thoreau, Claire Bouix-Peter
  • BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20190071433
    Abstract: Benzimidazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: March 7, 2019
    Inventors: Branislav MUSICKI, Gilles OUVRY, Etienne THOREAU, Claire BOUIX-PETER
  • TETRAHYDROQUINOLINE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20180265500
    Abstract: Tetrahydroquinoline sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma (ROR?t) are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: September 20, 2018
    Inventors: Branislav MUSICKI, Claire BOUIX-PETER, Gilles OUVRY, Etienne THOREAU
  • BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20180170869
    Abstract: Benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonist of retinoid-related orphan receptor gamma (ROR?t) are described. A pharmaceutical composition including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-medicated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 21, 2018
    Inventors: Branislav MUSICKI, Claire BOUIX-PETER, Gilles OUVRY, Etienne THOREAU
  • NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS
    Publication number: 20180050992
    Abstract: The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.
    Type: Application
    Filed: December 22, 2015
    Publication date: February 22, 2018
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Francois Fournier, Laurence Clary, Etienne Thoreau
  • INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20170342062
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: November 30, 2017
    Inventors: Branislav MUSICKI, Gilles OUVRY, Etienne THOREAU, Claire BOUIX-PETER
  • Biphenyl compound selective agonists of gamma RAR receptors
    Patent number: 8362082
    Abstract: Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: January 29, 2013
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Etienne Thoreau
  • Biphenyl compound selective agonists of gamma RAR receptors
    Patent number: 8106235
    Abstract: Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: January 31, 2012
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Etienne Thoreau
  • BIPHENYL COMPOUND SELECTIVE AGONISTS OF GAMMA RAR RECEPTORS
    Publication number: 20120016031
    Abstract: Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.
    Type: Application
    Filed: September 23, 2011
    Publication date: January 19, 2012
    Applicant: GALDERMA Research & Development
    Inventors: Thibaud BIADATTI, Etienne Thoreau